A cautionary tale of virus and disease by Weiss, Robin A
A year ago, Lombardi et al. [1] reported in Science the 
detection of a retrovirus in 67% of persons suffering from 
chronic fatigue syndrome (CFS) compared with a 3.7% 
infection rate in healthy controls. The virus is known as 
xenotropic murine related retrovirus (XMRV) because its 
sequence is closely related to, but distinct from, those of 
well  known  strains  of  xenotropic  murine  leukemia 
viruses  (XMLVs).  In  CFS  blood  samples,  XMRV  was 
readily detected by PCR amplification of the viral genome, 
by the expression of viral antigens in infected cells and by 
virus  isolation  and  propagation  in  cell  culture.  These 
findings  have  since  become  controversial,  with  reports 
from four independent groups of investigators [2-5] who 
have failed to find evidence of any association between 
XMRV infection and CFS. Most recently, to add to the 
confusion,  a  new  paper  [6]  reports  an  association 
between CFS and a different retrovirus - a report erro-
neously  described  in  some  of  the  press  coverage  as 
confirmation of the original report of Lombardi et al.
Many people suffering from CFS greeted the first report 
[1] with enthusiasm and relief because of the persistent 
skepticism of physicians about whether CFS is a defined 
disease with a single cause. If the association of at least two 
kinds  of  murine-related  retrovirus  with  the  syndrome 
stands the test of time, it will represent a very important 
discovery. CSF patients would then be assured of having a 
recognized  infection  with  the  possibility  of  effective 
treatment - indeed, some of them are already so convinced 
they  have  started  treatment  with  anti-retroviral  drugs 
(first  developed  against  HIV)  in  the  hope  of  clearing 
infection and their symptoms. Blood banks would have 
to consider whether to screen donations for the impli-
cated  retroviruses.  But  before  such  steps  could  be 
justified, it will be essential to perform truly blinded tests 
on  cases  and  proper  controls  in  several  laboratories. 
Profoundly disappointing as this would be for patients, 
without  such  additional  studies,  laboratory  artifacts 
cannot be ruled out; also, with the signal exceptions of 
HIV and human T-lymphotrophic virus, the history of 
retroviral  associations  with  human  disease  is  not 
encouraging.
Mouse gammaretroviruses and human disease
XMRV  is  a  gammaretrovirus  closely  related  but  not 
identical to other XMLV strains. These viruses have the 
curious property that they can infect foreign cells, such 
as human cells, in culture, but do not re-infect murine 
cells [7,8]. The term xenotropic was coined by Jay Levy in 
1972  to  distinguish  these  viruses  from  ecotropic  MLV, 
which infects mouse cells but not human cells. There is 
also a polytropic MLV that can infect the cells of both 
species, and it is this virus that most closely resembles 
the retrovirus identified in the latest claim for a retroviral 
association  with  CFS  [6].  XMLV  is  carried  by  most 
strains of mice in the form of endogenous viral genomes 
integrated in the chromosomes of the mouse germ line 
and  inherited  as  Mendelian  traits,  but  that  can  be 
activated  to  emerge  as  potentially  infectious  virus 
particles. The tropism of the viruses (that is, the cells and 
species they can infect) is largely determined by the cell 
surface receptors [9] to which the viral envelope glyco-
proteins bind before the virus gains entry into the cell. 
Gammaretroviruses like XMRV are capable of crossing to 
host species of quite different taxa; for instance, a virus of 
south-east Asian rodents has jumped to gibbons and to 
koalas [8,10]. So given our frequent proximity to mice, 
infection  of  humans  by  murine  retroviruses  is  not 
inherently unlikely.
XMRV  was  first  described  in  humans  in  a  subset  of 
patients with prostate cancer [11]. This subset was homo-
zygous for a mutation in the gene for RNase L, which is 
activated in response to the type 1 interferons, which are 
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anitviral  defenses.  RNase  L  degrades  double-stranded 
RNA  and  thereby  prevents  viruses  from  replicating.  It 
seemed  reasonable,  therefore,  to  suppose  that  people 
defec  tive  for  RNAse  L  might  be  more  susceptible  to 
infection by a murine virus, either as a direct zoonotic 
transfer from a mouse or from virus already circulating 
from  human  to  human.  However,  the  association  of 
XMRV with prostate cancer had a number of mystifying 
features. XMRV appeared to be integrated into human 
DNA but, curiously, the virus was located in the stromal 
cells rather than the carcinoma cells in tumor biopsies 
[11]. Stromal cells express a receptor for XMRV [9], but 
an independent group that reported XMRV in late-stage 
prostate tumors [12] detected the virus in the cancer cells 
themselves  rather  than  the  stroma,  and  found  no 
association with the RNase L polymorphism. As with the 
postulated association of XMRV with CFS, other groups 
in Europe could not find the virus in prostate cancers. 
Thus, the status of XMRV in relation to prostate cancer 
remains  uncertain.  Is  it  present  in  the  stroma  or  the 
carcinoma cells? Is there a genuine association with the 
host polymorphism in RNase L? Is it really present only 
in North American patients?
Pat Moore, the co-discoverer of two human oncogenic 
viruses  (Kaposi’s  sarcoma  herpesvirus  and  Merkel  skin 
cancer polyomavirus) points out on the F1000 blog how 
surprising the CFS findings results reported by Lombardi 
et al. [1] are, if taken at face value. XMRV appears to be 
present in peripheral blood mononuclear cells (PMBCs) 
at extraordinarily high viral loads. Practically every cell in 
stimulated  PBMC  cultures  apparently  expresses  viral 
envelope antigen (according to unimodal flow cytometry 
peaks  in  each  of  the  five  patients  analyzed),  and  the 
western blot shows a higher level of envelope expression 
in  patients’  PBMCs  than  in  the  positive  control  of  an 
experimentally XMRV-infected cell line. If these results 
are  confirmed  as  specific  rather  than  antigenic  cross-
reactions, according to my reckoning a higher proportion 
of PBMCs could be infected in CFS than is seen in any 
other retroviral infection of humans or animals. Yet only 
9 of 18 of these highly antigen-positive patients produced 
serum  antibodies  to  the  envelope.  The  response  of 
Lombardi et al. to Moore’s comments was that they had 
not made it sufficiently clear in their paper [1] that the 
PBMCs had been cultured for 7 to 14 days in order to 
amplify the amount of XMRV.
Ubiquitous murine retroviruses
Investigators who have no special interest in retroviruses 
may not realize that XMLV is widespread in many labora-
tories  conducting  biological  or  medical  research. 
Numerous human cancer cell lines have been propagated 
at  some  stage  of  their  history  as  xenografts  in 
immuno  deficient  mice  and  have  acquired  XMLV 
infection  from  the  mouse.  Other  human  cells  have 
acquired  the  virus  through  horizontal  infection  in  the 
laboratory  owing  to  the  less  stringent  containment 
practiced in non-virological laboratories. XMLV may also 
be  widespread  in  laboratory  reagents.  For  example, 
28  years  ago  I  reported  that  in  my  laboratory,  50%  of 
murine  hybridomas  producing  monoclonal  antibodies 
also secreted XMLV. Another example is HotStart Taq 
polymerase, which has an inhibitory murine monoclonal 
antibody  blocking  cold  polymerase  activity  and  may 
therefore contain traces of XMLV. Thus, the opportunities 
for  XMLV  sequence  contamination  are  rife,  and  any 
claims about the identification of viruses of this family, 
including XMRV and polytropic MLV, in human clinical 
samples need to be regarded with some caution.
I would be happy to accept that if XMRV is associated 
with  CFS,  so  could  polytropic  MLV  be.  What  I  find 
extraordinary, however, is that only XMRV was found by 
Lombardi et al. [1], whereas only polytropic MLV was 
detected by Lo et al. [6]. Given that the samples analyzed 
by Lo et al. were collected over several years from persons 
with  no  contact  with  each  other  and  widely  dispersed 
across  states  in  New  England  [6],  it  does  not  make 
epidemiological  sense  that  the  two  types  of  CFS-
associated  MLV  segregate  according  to  the  laboratory 
performing the tests.
If the positive results linking XMRV with CFS are not 
laboratory  artifacts,  how  can  we  explain  the  failure  of 
other  investigators  to  replicate  the  findings?  Much 
discussion (for example, in the chatroom of the BioMed 
Central  journal  Retrovirology  following  the  negative 
reports  [4,5])  revolves  around  the  suggestion  that  the 
discrepancies  might  be  explained  by  variation  in  the 
diagnostic criteria for CFS. It is a syndrome that has a 
fairly  broad  spectrum  of  signs  and  symptoms  and  the 
precise  definitions  used  by  the  different  investigating 
groups were not identical. But while different inclusion 
criteria for CFS could explain a difference between, say, a 
50%  and  a  67%  detection  frequency  of  XMRV  in  CFS 
samples,  surely  it  cannot  account  for  the  difference 
between 0% and 67% found in these reports.
Rumor viruses
My own skepticism also derives from a strong feeling of 
déjà vu. Following the discovery of reverse transcriptase 
40  years  ago,  several  laboratories  started  looking  for 
retroviruses (or RNA tumor viruses as they were then 
called) in human tumors, and in 1972 one was discovered 
in  a  human  cell  line  derived  from  a  pediatric  rhabdo-
myosarcoma - a tumor of myoblasts. It took 2 years for 
three independent groups to show that the virus, hailed 
as  the  first  human  RNA  tumor  virus,  was  actually  a 
previously  unknown  xenotropic  retrovirus  of  cats  [7]. 
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passed as a xenograft in the brain of a fetal kitten as an 
immunologically privileged site (nude mice had not yet 
become available).
Since  that  time,  there  has  been  a  long  succession  of 
‘rumor’ viruses posing as tumor viruses and promulgated 
as  the  cause  of  chronic  human  diseases;  these  are 
reviewed  in  detail  elsewhere  [13].  For  instance,  the 
proposition that murine mammary tumor virus (a beta-
retrovirus) is present in human breast cancer has been in 
circulation since 1972; but to my mind, the evidence is no 
stronger  for  simple  reiteration.  The  stimulus  for  the 
invitation to write the comprehensive survey of rumor 
viruses mentioned above [13] was the publication of a 
retraction of what we imagined was our own discovery of 
a novel human retrovirus. In 1997 we reported finding an 
envelope-defective  retrovirus  genome  in  patients  with 
rheumatoid arthritis, only to discover 4 years later (and 
after two groups, in the USA and Sweden, had indepen-
dently ‘confirmed’ our findings) that our putative human 
virus  was  actually  a  previously  unknown  endo  genous 
betaretrovirus of rabbits.
If  virus  detection  resulted  from  laboratory  contami-
nation, why was our virus detected more frequently in 
clinical disease samples than in the healthy controls? We 
have no good answer to this question, but I suspect it 
may simply be that the vials containing clinical specimens 
tend to be handled more often than a job-lot of healthy 
blood  samples.  If  the  healthy  samples  had  come  from 
strictly  derived  case-control  collections  in  which  the 
control vials were handled in exactly the same manner, 
for the same time and with the same frequency as the 
vials  containing  the  clinical  specimens  (which  has  not 
been done for CFS), we might not have observed the bias 
towards detection in cases above controls. Our laboratory 
controls - water specimens interspersed between PBMC 
DNA extracts - were reassuringly negative. So I raise an 
eyebrow when investigators declare that contamination is 
‘out of the question’; once bitten, twice shy.
Much argument circulates among the protagonists and 
skeptics of XMRV about which PCR primers should be 
used and the exact conditions of detection. These matters 
are, of course, important, but it seems to me that if a 
virus is genuinely present and is detectable by a single 
round  of  PCR  amplification,  it  should  be  confirmable 
with  several  alternative  sets  of  primers  for  different 
regions of its genome. The recently reported [6] murine 
retrovirus distinct from XMRV, more closely related to 
polytropic MLV (should it be called PMRV?), was also 
detected by single-round PCR; but in contrast to Lom-
bardi et al. [1], the authors of this paper have, to date, 
reported no virus isolation or serological tests.
Various  viruses,  including  herpesviruses  and  entero-
viruses,  have  been  implicated  in  CFS.  The  possible 
involvement of a retrovirus was first mooted 19 years ago 
[14]. In that paper, human T-lymphotropic virus type II 
(HTLV-II) was detected in a study remarkably similar to 
those reported in the new papers [1,6] (which do not cite 
it). As in the current story, two independent groups, in 
the  USA  and  UK,  were  unable  to  confirm  any  link 
between HTLV-II and CFS. The original paper was never 
retracted and it appears to be largely forgotten. I wonder 
which papers will be cited 19 years from now.
SV40 in human tumors
The current controversy is also highly reminiscent of the 
storm that raged in the 1990s over the presence of simian 
virus 40 (SV40) in human tumors [15]. This polyomavirus 
occurs naturally in macaque monkeys and is related to 
human polyomaviruses BK and JC, both of which infect 
the  majority  of  the  human  population.  SV40  was  dis-
covered in 1960 by Sweet and Hilleman as a contaminant 
of  rhesus  monkey  kidney  cultures  used  for  the 
propagation of poliovirus vaccine. This led the vaccine 
manufacturers  to  switch  cell  substrates  to  SV40-free 
African green monkey kidney cultures, which, more than 
20  years  later,  were  in  turn  found  to  harbor  a  simian 
version  of  immunodeficiency  virus  (SIVagm);  luckily, 
however,  this  strain  of  SIV  does  not  infect  humans. 
Anyway,  the  change  in  vaccine  production  did  not 
happen until some millions of people had been immu-
nized with poliovirus vaccine stocks prepared in rhesus 
kidney cells so there was potential exposure on a massive 
scale. Accurate serological surveys for SV40 infection in 
humans were obscured by cross-reactions with the human 
BK and JC viruses (and during the past 4 years, three novel 
strains of human polyomavirus have been reported).
SV40 is highly oncogenic in new-born rodents but is not 
known to be oncogenic in monkeys. Likewise, BK and JC 
viruses  can  cause  cancer  in  hamsters  but  not  in  their 
natural host, the human. Epidemiological studies were set 
up to establish whether any increase in cancer occurred in 
populations  exposed  to  the  potentially  contaminated 
poliovirus vaccines, but no excess cancer incidence was 
found. In 1992, however, SV40 was reported in pediatric 
cases of neurological tumors, patients whose parents, or 
more likely grandparents, might have been exposed to the 
tainted  vaccine.  Positive  sightings  of  SV40  were  soon 
reported  in  other  human  tumors  too,  especially 
mesothelioma and osteosarcoma. If these reports could be 
confirmed, it would imply that SV40 is now circulating as a 
transmissible  virus  in  humans  and  that  it  is  oncogenic. 
Several  other  investi  gators,  however,  could  not  find 
evidence of SV40 in tumor biopsies [15].
The  protagonists  of  SV40  in  human  tumors  said  the 
doubters did not know how to conduct proper, specific 
PCR  tests;  the  skeptics  pointed  out  how  easy  it  is  for 
SV40  to  contaminate  samples.  SV40  sequences  are 
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represented  in  so  many  plasmids  and  reagents.  Sasha 
Voevodin  and  Preston  Marx  recently  stated  that  ‘The 
genomic DNA of SV40 is the most intensively manipu-
lated  DNA  molecule  (per  base  pair)  in  the  history  of 
molecular biology’ [10]. MLV must be a close runner-up 
given the frequency with which we use retroviral vectors 
derived from them.
The National Cancer Institute and the Food and Drug 
Administration (FDA) did the right thing for SV40, just 
as is now proposed by the FDA for XMRV, and sponsored 
a  multi-center  study  of  strictly  masked  samples  of 
mesothelioma  and  normal  lung  tissue,  and  included 
positive controls deliberately spiked with the virus [16]. 
Only the positive controls came through as consistently 
containing SV40 DNA. Drafting a timely report, however, 
proved to be far more difficult than performing the tests, 
owing to back-tracking by some protagonists concerning 
earlier agreement on the methods and the specimens to 
be used, and I think that the federal agencies tried too 
hard  to  reach  a  consensus  where  none  existed.  The 
Institute of Medicine later produced a report stating that 
no conclusive evidence of SV40 transmission to humans 
from poliovirus vaccines was evident [15]. The proposed 
XMRV survey of masked samples could benefit from the 
experience of the SV40 exercise.
Absence of evidence and evidence of absence
It is noteworthy that positive findings are often published 
in high profile journals, while the negative ones find their 
way to specialist journals. In the case of XMRV, two of the 
negative  reports  were  accepted  by  BMC  Biology’s  sister 
journal Retrovirology [4,5], which is becoming well estab-
lished as the standard-bearer of its field. The recent paper 
by  Switzer  et  al.  [5],  which  examined  properly  blinded 
samples,  perhaps  has  too  modest  a  title:  ‘Absence  of 
evidence of XMRV virus infection in persons with CFS 
and healthy controls in the United States’ . I would go further 
and suggest that they found firm evidence of absence.
Despite  the  arguments  and  observations  that  I  have 
raised, I feel some discomfort as a retrovirus specialist in 
casting doubt on the link between XMRV and prostate 
cancer and CFS. During the past two decades I have spent 
far more time than I wished arguing against those who 
deny that HIV is the cause of AIDS. Moreover, I have acted 
as a Jeremiah, warning of the potential hazards of clinical 
xenotransplantation  in  case  endoge  nous  retroviruses  of 
pigs  (gammaretroviruses  related  to  MLV)  might  cause 
havoc in humans treated with animal cells or tissues.
In this journal, Martin Raff recently answered questions 
about the biological basis of autism [17] and repudiated 
the notion that either infection or MMR immunization is 
the culprit. The difficulties of CFS are similar to those of 
autism, precise diagnosis being a major problem; and at 
the  time  of  writing,  the  question  of  murine  retrovirus 
infection in CFS remains open. Rumor viruses are seldom 
eradicated; they remain latent, waiting to be reactivated 
in a new disease. Subtle diseases of unknown cause will 
remain  susceptible  to  rumor  viruses  for  as  long  as  no 
other etiology is established.
Published: 27 September 2010
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